NORD® Corporate Council Members 2008
NORD is grateful to the following companies who are active members of the Corporate Council

Accredo Health, Inc.
Acorda Therapeutics
Actelion Pharmaceuticals US, Inc.
Alexion Pharmaceuticals, Inc.
Allergan
Altus Pharmaceuticals
Amicus Therapeutics, Inc.
Antigenics, Inc.
Applied Genetic Technologies Corp.
Aspreva Pharmaceuticals
Astra Zeneca Pharmaceuticals LP
Aton Pharma Inc
Avigen, Inc.
Bausch & Lomb Pharmaceuticals
Bausch & Lomb Surgical Division Retina Marketing
BioMarin Pharmaceuticals, Inc.
Brushcreek LLC/Errant Gene Therapeutics
Celgene Corporation
Duchesnay, Inc.
Endo Pharmaceuticals
Engage Health, Inc.
FFF Enterprises
FoldRX Pharmaceuticals, Inc.
Genzyme Therapeutics
Hemophelia Health Services
HPS Group LLC
Hyperion Therapeutics
IDIS Pharmaceuticals
Impax Laboratories, Inc.
IKARIA
Insmed Incorporated
Jazz Pharmaceuticals
Johnson & Johnson
Mark Krueger & Associates, Inc.
Medtronic, Inc.
Millennium Pharmaceuticals
Neurochem, Inc.
NexGenix Pharmaceuticals
Prestwick Pharmaceuticals
PTC Therapeutics Inc
Purdue Pharma
Questcor Pharmaceuticals, Inc.
Rare Disease Therapeutics, Inc.
Sanofi-Aventis, Inc.
Shire Pharmaceuticals
Sigma-Tau Pharmaceuticals
Ucyclyd Pharma (Medicis)
United Therapeutics Corporation
ZioPharm Oncology, Inc.

For information on the NORD Corporate Council please contact:
Jean Campbell, Vice President of Development
National Organization for Rare Disorders (NORD)
55 Kenosia Avenue Danbury, CT 06813
Phone - 203-744-0100
Fax - 203-798-2293
email - jcampbell@rarediseases.org

back to Corporate Council Homepage